Search
Adefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedAdefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment
Proflavine
go.drugbank.com/drugs/DB01123ApprovedInvestigationalTopical antiseptic used mainly in wound dressings.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric … Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital
Cipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigational[L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026. … and maintenance of general anesthesia in children and adolescents.
Esculin
go.drugbank.com/drugs/DB13155ApprovedEsculin is found in barley. … ) and in daphnin (the dark green resin of Daphne mezereum).
Hemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … Naldemedine is an opioid receptor antagonist [FDA Label].
NV-52
go.drugbank.com/drugs/DB05673ExperimentalNV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigational[A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency